Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Brown

Gastroenterology Dallas, TX Medical Doctor

NPI 1265903652 CMS profile 5694550

5323 Harry Hines Blvd Rm L5.238, Dallas, TX 75390

Open in the dashboard

General payments

$5,519,502

310 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Brown of Dallas, TX is reported in the CMS Open Payments database as having received $5,519,502 across 310 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $824,295 44
2024 General $825,187 70
2023 General $827,946 51
2022 General $795,459 43
2021 General $751,525 19
2020 General $746,952 18
2019 General $748,137 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Brown
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Michael Brown were reported at $824,295. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Michael Brown Gastroenterology median Middle half National median
2019 $748,137 $417 $126–$1,100 $163
2020 $746,952 $224 $74–$624 $114
2021 $751,525 $352 $106–$1,054 $132
2022 $795,459 $448 $129–$1,270 $149
2023 $827,946 $533 $150–$1,390 $160
2024 $825,187 $605 $160–$1,606 $164
2025 $824,295 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $5,519,457 307 payments
  2. Pfizer Inc. $28 2 payments
  3. Novo Nordisk Inc $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $3,239,755 36 payments
  2. Current or prospective ownership or investment interest $1,800,087 6 payments
  3. Travel and Lodging $467,632 136 payments
  4. Food and Beverage $12,028 132 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS $28 2 payments
  2. PAXLOVID $28 2 payments
  3. Ozempic $18 1 payment
  4. RYBELSUS $18 1 payment
  5. NURTEC ODT $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

310 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record